JP2023514732A - アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 - Google Patents

アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 Download PDF

Info

Publication number
JP2023514732A
JP2023514732A JP2022550240A JP2022550240A JP2023514732A JP 2023514732 A JP2023514732 A JP 2023514732A JP 2022550240 A JP2022550240 A JP 2022550240A JP 2022550240 A JP2022550240 A JP 2022550240A JP 2023514732 A JP2023514732 A JP 2023514732A
Authority
JP
Japan
Prior art keywords
use according
pharmaceutical composition
improvement
individual
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514732A5 (https=
Inventor
リチャード グラハム
ケ ウー
マスード ファヒド
モハメド ディバス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2023514732A publication Critical patent/JP2023514732A/ja
Publication of JP2023514732A5 publication Critical patent/JP2023514732A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022550240A 2020-02-20 2021-02-19 アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 Pending JP2023514732A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062979214P 2020-02-20 2020-02-20
US62/979,214 2020-02-20
PCT/US2021/018906 WO2021168349A1 (en) 2020-02-20 2021-02-19 Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision

Publications (2)

Publication Number Publication Date
JP2023514732A true JP2023514732A (ja) 2023-04-07
JP2023514732A5 JP2023514732A5 (https=) 2024-02-28

Family

ID=74875311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550240A Pending JP2023514732A (ja) 2020-02-20 2021-02-19 アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用

Country Status (12)

Country Link
US (2) US20210260041A1 (https=)
EP (1) EP4106728A1 (https=)
JP (1) JP2023514732A (https=)
KR (1) KR20220157392A (https=)
CN (1) CN115443125A (https=)
AU (1) AU2021224232A1 (https=)
BR (1) BR112022016730A2 (https=)
CA (1) CA3168767A1 (https=)
IL (1) IL295782A (https=)
MX (1) MX2022010317A (https=)
TW (1) TW202139998A (https=)
WO (1) WO2021168349A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3209420A1 (en) 2021-02-24 2022-09-01 Peter Jarrett Intracanalicular depot inserter device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507216A (ja) * 1993-12-17 1997-07-22 ザ、プロクター、エンド、ギャンブル、カンパニー ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
CN102821753A (zh) 2010-01-22 2012-12-12 阿勒根公司 前房内持续释放治疗药植入物
WO2014159576A1 (en) * 2013-03-14 2014-10-02 Allergan, Inc. Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
WO2014143754A2 (en) 2013-03-15 2014-09-18 Allergan, Inc. Prostamide-containing intraocular implant
EP2978406A1 (en) 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
AU2014248460B2 (en) 2013-04-01 2019-04-11 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
TW202021584A (zh) * 2018-08-21 2020-06-16 美商歐樂根公司 α2 腎上腺素受體促效劑用於改善視力之用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507216A (ja) * 1993-12-17 1997-07-22 ザ、プロクター、エンド、ギャンブル、カンパニー ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途

Also Published As

Publication number Publication date
EP4106728A1 (en) 2022-12-28
MX2022010317A (es) 2023-01-24
AU2021224232A1 (en) 2022-10-13
CA3168767A1 (en) 2021-08-26
US20210260041A1 (en) 2021-08-26
BR112022016730A2 (pt) 2022-11-08
TW202139998A (zh) 2021-11-01
KR20220157392A (ko) 2022-11-29
US20240335425A1 (en) 2024-10-10
CN115443125A (zh) 2022-12-06
WO2021168349A1 (en) 2021-08-26
IL295782A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
US20240382462A1 (en) Presbyopia treatments
KR102472774B1 (ko) 안과용 약학 조성물 및 이와 관련된 용도
BRPI0821683B1 (pt) uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz
US20240358682A1 (en) Use of alpha-2-adrenergic receptor agonists for improving vision
US20240390330A1 (en) Alpha-2-adrenergic receptor agonists for reducing redness and increasing whiteness in eyes and other ophthalmic purposes
US11077053B2 (en) Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
US20240335425A1 (en) Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision
US20260124178A1 (en) Presbyopia treatments
HK40053072A (en) The use of alpha-2-adrenergic receptor agonists for improving vision

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250908